Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Gajofatto

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Multiple Sclerosis and Related Disorders|July 27, 2016
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosisAlberto Gajofatto
Drug Design, Development and Therapy|November 16, 2017
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to dateAlberto Gajofatto
Expert Opinion on Investigational Drugs|February 20, 2018
Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosisAlberto Gajofatto, Marco Turatti
Drugs of Today (Barcelona, Spain : 1998)|February 2, 2022
Ofatumumab for relapsing forms of multiple sclerosisAlberto Gajofatto, Riccardo Orlandi
World Journal of Clinical Cases|August 6, 2015
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Alberto Gajofatto, Maria Donata Benedetti
Multiple Sclerosis and Related Disorders|June 14, 2022
Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, ItalyRiccardo Orlandi, Sara Mariotto, Alberto Gajofatto
Expert Review of Neurotherapeutics|November 14, 2014
Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophyMassimiliano Calabrese, Alberto Gajofatto, Maria Donata Benedetti
Expert Review of Neurotherapeutics|November 5, 2016
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectivesAlberto Gajofatto, Marco Turatti, Maria Donata Benedetti
Neuroepidemiology|April 24, 2025
Life and Death with Multiple Sclerosis: 20 Years Reappraisal of Verona Prevalence CohortRiccardo Orlandi, Fabio Bonomi, Francesca Calabria, et al.
Drug, Healthcare and Patient Safety|December 31, 2015
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisAlberto Gajofatto, Marco Turatti, Salvatore Monaco, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|July 27, 2016
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosisAlberto Gajofatto
Drug Design, Development and Therapy|November 16, 2017
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to dateAlberto Gajofatto
Expert Opinion on Investigational Drugs|February 20, 2018
Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosisAlberto Gajofatto, Marco Turatti
Drugs of Today (Barcelona, Spain : 1998)|February 2, 2022
Ofatumumab for relapsing forms of multiple sclerosisAlberto Gajofatto, Riccardo Orlandi
World Journal of Clinical Cases|August 6, 2015
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Alberto Gajofatto, Maria Donata Benedetti
Multiple Sclerosis and Related Disorders|June 14, 2022
Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, ItalyRiccardo Orlandi, Sara Mariotto, Alberto Gajofatto
Expert Review of Neurotherapeutics|November 14, 2014
Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophyMassimiliano Calabrese, Alberto Gajofatto, Maria Donata Benedetti
Expert Review of Neurotherapeutics|November 5, 2016
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectivesAlberto Gajofatto, Marco Turatti, Maria Donata Benedetti
Neuroepidemiology|April 24, 2025
Life and Death with Multiple Sclerosis: 20 Years Reappraisal of Verona Prevalence CohortRiccardo Orlandi, Fabio Bonomi, Francesca Calabria, et al.
Drug, Healthcare and Patient Safety|December 31, 2015
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisAlberto Gajofatto, Marco Turatti, Salvatore Monaco, et al.
Pageof 9